TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01232075
Drug: Clomiphene citrate regimen
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate(Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg/day is administered from cycle day 3 to 7.~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy .
Study: NCT02766582
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV every 21 days at 200 mg
Study: NCT02766582
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV every 21 days
Study: NCT02766582
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion (80mg/m2) every 7 days for 6 cycles
Study: NCT03998696
Drug: Cisplatin 100 mg/m2
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2, three weekly, concurrent with Radiotherapy
Study: NCT03664388
Drug: Dual antiplatelet therapy with ticagrelor/prasuglre
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy
Study: NCT00749567
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150mg daily, continuously, until disease progression or the appearance of unacceptable toxicity
Study: NCT00749567
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression or the appearance of unacceptable toxicity
Study: NCT03205046
Drug: acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.
Study: NCT03205046
Drug: vistusertib
Normalized name: Vistusertib
DrugBank: Vistusertib (DB11925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase
Study: NCT00490399
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00490399
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01649999
Drug: peficitinib
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: oral
Study: NCT04426552
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: will have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
Study: NCT04426552
Drug: sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
Study: NCT01935492
Drug: Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1. st line:~   * Paclitaxel and bevacizumab: 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * Bevacizumab until PD or unacceptable toxicity~  * At PD patients will go to the 2nd treatment line.~2. nd line:~   * Non-pegylated liposomal doxorubicin (Myocet®) (or capecitabine): 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * At PD patients will go to the 3rd treatment line. If possible, it is advised to cross-over from 2nd line non-pegylated liposomal doxorubicin to 3rd line capecitabine.
Study: NCT01935492
Drug: Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Arm B~1. st line~   * Paclitaxel and bevacizumab: 4 cycles, unless PD or unacceptable toxicity~  * Bevacizumab until PD or unacceptable toxicity~  * At PD \< 3 months after last paclitaxel start 2nd treatment line.~  * At PD ≥ 3 months after last paclitaxel, start another 4 cycles~  * Bevacizumab until the next PD or unacceptable toxicity~  * At the next PD start the 2nd treatment line.~2. nd line:~   * Myocet® or capecitabine: 4 cycles, unless PD or unacceptable toxicity~  * At PD \< 3 months start the 3rd treatment line. If possible, advised to cross-over from 2nd line Myocet® to 3rd line capecitabine.~  * At PD ≥ 3 months after last administration of Myocet® or capecitabine, start another 4 cycles of Myocet® or capecitabine~  * At the next PD start 3rd treatment line.
Study: NCT04539106
Drug: intravitreal injection of Ranibizumab
Normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus
Study: NCT00226447
Drug: Pegylated Interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00226447
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02123472
Drug: Cephalexin
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Orally
Study: NCT03952377
Drug: SX600
Normalized name: Sildenafil citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transforaminal Epidural Injection
Study: NCT04646707
Drug: Erector Spinae (ESP) Block with Lidocaine/Bupivacaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
Study: NCT00001378
Drug: fenretinide
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01676636
Drug: Traditional Tablet
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The traditional tablets will be swallowed with liquid. Each tablet will contain 500 mg of calcium (as calcium carbonate), thus participants will be asked to take 3 per day.. Participants will be asked to take the tablets with a liquid of their choosing with a meal. Traditional tablets will function as a control in this study, as they represent what is widely available on the market in Bangladesh.
Study: NCT01676636
Drug: Chewable tablets
Normalized name: Pepcix Chewable Tablets
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable tablets are chewed in the absence of additional water. Each chewable tablet will contain 300 mg of calcium (as calcium carbonate), thus participants will be asked to take 5 per day. Participants will be asked to consume the chewable tablets with a meal.
Study: NCT03449277
Drug: Oral Tablet
Normalized name: Oral Tablet
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral labetalol tablets and oral nifedipine tablets
Study: NCT02874820
Drug: Idazoxan
Normalized name: Idazoxan
DrugBank: Idazoxan (DB12551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan dose up to 80mg
Study: NCT00891540
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine 0.5%
Study: NCT00891540
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine 0.2%
Study: NCT03687463
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine for injection
Study: NCT00271284
Drug: insulin glulisine / insulin glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: insulin glargine administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
Study: NCT00271284
Drug: insulin glulisin / insulin detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: insulin detemir administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
Study: NCT01466829
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 microgram daily. S.c
Study: NCT00004913
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004913
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00771654
Drug: Phentermine
Normalized name: Phentermine
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive Phentermine 37.5mg everyday for one year
Study: NCT00557700
Drug: Administration of inhaled tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of inhaled tiotropium bromide
Study: NCT03294382
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 5U botulinum toxin in 0.1 mL normal saline, injected in two points at one side, 2.5U per point, local injection
Study: NCT02205489
Drug: Alemtuzumab GZ402673
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:concentration for solution Route of administration: intravenous infusion
Study: NCT04509440
Drug: isotonic dextrose 5% in water (D5W) solution
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurol prolotherapy (NP) is the subcutaneous perineural injection of isotonic dextrose 5% in water (D5W) solution.
Study: NCT03813160
Drug: Lenabasum 20 mg
Normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT03813160
Drug: Lenabasum 5 mg
Normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT02205489
Drug: cetirizine
Normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT02205489
Drug: ranitidine
Normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT02205489
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT02205489
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:solution Route of administration: intravenous
Study: NCT02205489
Drug: aciclovir
Normalized name: Aciclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT02205489
Drug: esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT02205489
Drug: paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT00875693
Drug: CPX-351
Normalized name: CPX
DrugBank: DPCPX (DB12946)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio.
Study: NCT02445547
Drug: received hormone maintenance therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03236324
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mL 0.9% saline administered on each side as bilateral TFP blocks
Study: NCT02366091
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
Study: NCT02338232
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02164084
Drug: SB204
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SB204 Gel with hydrogel
Study: NCT00042471
Drug: Pramlintide acetate
Normalized name: Pramlintide Acetate
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
Study: NCT00165815
Drug: ARICEPT
Normalized name: Aricept
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02583217
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To compare ketamine+propofol versus remifentanyl+propofol to maintain good laryngeal mask insertion conditions
Study: NCT02511873
Drug: Fycompa
Normalized name: FYCOMPA
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will take Fycompa for 6 weeks with a dose range of 2mg to 8mg daily
Study: NCT02769832
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 100 mg/m2, day 1 and day 8 of a 21-day cycle
Study: NCT02583217
Drug: remifentanyl
Normalized name: Remifentanyl
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02583217
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02760225
Drug: 89Zr-Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
Study: NCT00667251
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
Study: NCT00667251
Drug: lapatinib ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1250 mg once daily (while given with taxane). 1500mg once daily (when given alone after taxane completion).
Study: NCT00667251
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
Study: NCT02769832
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m2, day 1 and day 8 of a 21-day cycle
Study: NCT03289403
Drug: Thyroxine
Normalized name: Thyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Patients will not receive immunomodulatory drugs
Study: NCT03781128
Drug: Lysergic Acid Diethylamide
Normalized name: Lysergic acid diethylamide
DrugBank: Lysergic acid diethylamide (DB04829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg, per os, 3 times within 3 weeks
Study: NCT04109508
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
Study: NCT04232332
Drug: Recombinant human nerve growth factor injection,experimental
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection once on the first day according to dose requirements
Study: NCT04232332
Drug: Recombinant human nerve growth factor injection,single dose
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection once on the first day according to dose requirements
Study: NCT04232332
Drug: Recombinant human nerve growth factor injection,multiple dose
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection once daily for 7 days according to dose requirements
Study: NCT02925416
Drug: Oritavancin
Normalized name: Oritavancin
DrugBank: Oritavancin (DB04911)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT00586092
Drug: bevacizumab, ABT-510
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Stage 1 (Cohorts -1, 2, 2, 3) ABT-510: 25, 50, 50, 100 mg SC BID\*, bevacizumab: 5, 5, 10, 10 mg/kg IV every 14 days\*~* Stage 2 (RPTD) ABT-510: X mg SC BID\*\*, bevacizumab: Y mg/kg IV every 14 days\*\*~  * Stage I is the dose escalation stage. Stage II will include an additional 20 patients (10 patients in each group) enrolled at the RPTD in two different schedules to better assess safety and biomarker correlates.~    * \*Both agents begin on Day 1 of Cycle 1.~      * \*\*At the RPTD, ½ the patients will begin ABT-510 (Dose X) on Day 1 and bevacizumab (Dose Y) on Day 15 and the other ½ of the patients will begin bevacizumab on Day 1 and ABT-510 on Day 15. This will allow for a collection of some preliminary data of wound angiogenesis effects of ABT-510 alone versus the combination and bevacizumab alone versus the combination.
Study: NCT03084380
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be administered at dose of 25mg/m2/d
Study: NCT01293682
Drug: Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In pill form, 45 micrograms once a week for 12 weeks
Study: NCT00577031
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5mg iv on day 1 of each 3 week cycle
Study: NCT00577031
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130mg/m2 iv on day 1 of each 3 week cycle
Study: NCT00577031
Drug: Xeloda
Normalized name: Xeloda
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 po bid on days 1-14 of each 3 week cycle
Study: NCT04635631
Drug: talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib will be administered orally on a continuous basis. Each cycle will consist of 28 days.
Study: NCT01157065
Drug: AL-78898A
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational treatment
Study: NCT01157065
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-vascular endothelial growth factor (VEGF) treatment
Study: NCT03712371
Drug: Chitosan
Normalized name: Chitosan
DrugBank: Chitosan low molecular weight (20-200 mpa.s) (DB14155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose for Chitosan is 500mg twice a day, the second dose level is 1000mg twice a day, the third dose level is 1500mg twice a day, and the fourth dose level is 2000mg twice a day. Each dose level lasts for 28 days.
Study: NCT01087736
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After random assignment, topiramate will be titrated up over 5 weeks. Dosing begins at 25 mg per day, and increase in the second week to 25 mg twice per day; in the third week to 50 mg twice/day; in the fourth week to 75 mg twice/day; in the 5th week to 100 mg twice/day; and in weeks 6-11 increased to and maintained at 100 mg in the morning and 200 mg at night. Patients will receive the highest dose tolerated, not to exceed 300 mg per day. Adjustments are permitted throughout titration. Once maximum tolerated dosage is reached, subjects will be asked to maintain dosage for remainder of the treatment phase. Upon completing the 6 week maintenance period subjects will taper off over a 7-day period (Week 12). If subjects experience significant side effects, the dosage may be adjusted.
Study: NCT00200356
Drug: Edaravone
Normalized name: Edaravone
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.
Study: NCT00200356
Drug: Sodium Ozagrel
Normalized name: Ozagrel
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.
Study: NCT02825797
Drug: 10-1074
Normalized name: Anti-hiv-1 human monoclonal antibody targeting v3 glycan supersite on the hiv-1 envelope protein (10-1074)
DrugBank: Zinlirvimab (DB18867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 10-1074
Study: NCT02691871
Drug: Apatinib (250 mg/d) + Docetaxel (60 mg/m2)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02691871
Drug: Apatinib (500 mg/d) + Docetaxel (60 mg/m2)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no